Inventiva S.A. American Depositary Receipt (IVA)
Inventiva: Significant Upside Potential Ahead Of Pivotal Liver Disease Readout
Inventiva receives a speculative strong buy rating, with a probability-weighted fair value of ~$15 per share versus ~$3.20 currently. Following strong Phase 2b NATIVE results, lanifibranor's pivotal Phase 3 NATiV3 readout is imminent, creating a major potential catalyst for the stock. The model yields a 40% probability of a $29 fair value per share, versus a 32% probability of near-total loss, with intermediate valuations reflecting varying degrees of clinical differentiation.
Inventiva Eyes Q4 2026 Phase III MASH Data as Lanifibranor Nears Key Test
Inventiva NASDAQ: IVA said it expects to report top-line results in the fourth quarter of 2026 from its fully enrolled Phase III NATiV3 trial of lanifibranor in patients with metabolic dysfunction-associated steatohepatitis, or MASH.
Inventiva S.A. (IVA) Q2 2026 Earnings Call Transcript
Inventiva S.A. (IVA) Q2 2026 Earnings Call Transcript
Inventiva Q2 Earnings Call Highlights
Inventiva NASDAQ: IVA said it remains on track to report top-line results from its Phase III NATiV3 trial of lanifibranor in metabolic dysfunction-associated steatohepatitis, or MASH, in the fourth quarter of 2026, after the last patient completed the study's 72-week visit earlier this month.
Inventiva S.A. (IVA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Inventiva S.A. (IVA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Inventiva: MASH Is Becoming A Combination Market Before Lanifibranor Arrives
Inventiva is positioned as a high-risk, clinical catalyst play targeting MASH with its oral pan-PPAR agonist, lanifibranor. Lanifibranor's potential lies in combination therapy, offering dual metabolic and anti-fibrotic benefits independent of weight loss, complementing GLP-1 and SGLT2 agents. Inventiva has secured sufficient liquidity through Q2 2027, with contingent access to further capital, and has strengthened governance ahead of the pivotal NATiV3 Phase 3 readout.
After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Inventiva (IVA)
Inventiva (IVA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Down 31.8% in 4 Weeks, Here's Why Inventiva (IVA) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Inventiva (IVA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Inventiva's Speculative Upside Through MASH Is Promising
Inventiva is now essentially a lanifibranor bet. Their prospects hinge on the upcoming Phase 3 NATiV3 readout, which we should get by Q4 2026. In my view, lanifibranor seems relatively differentiated after its Phase 2b results. Management is narrowing its focus solely on this MASH asset. IVA's balance sheet has sufficient financing to reach that readout. But please bear in mind that it's a binary outcome.
Inventiva S.A. (IVA) Q4 2025 Earnings Call Transcript
Inventiva S.A. (IVA) Q4 2025 Earnings Call Transcript
Are You Looking for a Top Momentum Pick? Why Inventiva S.A.
Does Inventiva S.A. Sponsored ADR (IVA) have what it takes to be a top stock pick for momentum investors?
Inventiva S.A. (IVA) Presents at 44th Annual J.P.
Inventiva S.A. (IVA) Presents at 44th Annual J.P.
